person · Reporting owner

COZADD BRUCE C

Disclosed activity across 3 companies

Tapewire entity: 819
SEC CIK: 0001193210

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CERUS CORPCERS · Entity 5431	Director	June 06, 2017	June 13, 2017
Jazz Pharmaceuticals plcJAZZ · Entity 818	Director	October 01, 2026	October 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CERUS CORP

Report date June 06, 2017 · Filed June 13, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,921	Reported balance After 2017-06-06 transaction · row 1 1 source row Row 1 · 2017-06-06 · Exercise / conversion · Acquired 10,133 · Balance 18,921 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2017-06-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-06 · Exercise / conversion · Disposed 10,133 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	15,853	Reported balance After 2017-06-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-06-07 · Grant · Acquired 15,853 · Balance 15,853 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2027-06-06	Direct	38,005	Reported balance After 2017-06-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-06-07 · Grant · Acquired 38,005 · Balance 38,005 F3: Not applicable. F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.

F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.

F3: Not applicable.

F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.

Jazz Pharmaceuticals plc

Report date October 01, 2026 · Filed October 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	345,875	Reported balance After 2026-10-01 transaction · row 1 1 source row Row 1 · 2026-10-01 · Sale · Disposed 6,000 · Balance 345,875 F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACELYRIN, Inc.

Report date May 21, 2025 · Filed May 23, 2025

Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2032-03-07	Direct	Reported balance After 2025-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-05-21 · Disposition to issuer · Disposed 183,434 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	Reported balance After 2025-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06	Direct	Reported balance After 2025-05-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.

F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.

F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 03, 2025 Filed Feb 5, 2025 22:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,500	$122.31	$183,465.00	Disclosure SEC source: 0001805688-25-000015 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,744 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
January 17, 2025 Filed Jan 22, 2025 23:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	13,840	$122.62	$1,697,060.80	Disclosure SEC source: 0001805688-25-000011 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 441,244 F2 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document
January 17, 2025 Filed Jan 22, 2025 23:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	29,559	$0.00	$0.00	Disclosure SEC source: 0001805688-25-000011 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 455,084 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified. Read SEC document
January 02, 2025 Filed Jan 6, 2025 21:22 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,500	$123.43	$185,145.00	Disclosure SEC source: 0001765581-25-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,525 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:24 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,000	$121.17	$242,340.00	Disclosure SEC source: 0001765581-24-000092 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,025 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: The Reporting Person acquired 49 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024. Read SEC document
November 01, 2024 Filed Nov 5, 2024 22:00 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$110.84	$110,840.00	Disclosure SEC source: 0001765581-24-000086 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,976 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 167 ordinary shares acquired on May 31, 2024 under a Section 423 Employee Stock Purchase Plan. Read SEC document
June 07, 2024 Filed Jun 11, 2024 23:17 UTC	ACELYRIN, Inc. SLRN · Entity 79310	GrantDirector Stock Option (right to buy) · Derivative	92,158	$0.00 Strike: $4.46	$0.00	Disclosure SEC source: 0001962918-24-000095 · wk-form4_1718147835.xml · derivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,158 Underlying: Common Stock · 92,158 shares Expires 2034-06-06 F1 · derivative.exercise_date: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document
March 05, 2024 Filed Mar 8, 2024 02:44 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	22,436	$117.53	$2,636,903.08	Disclosure SEC source: 0001765581-24-000028 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,809 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document
March 01, 2024 Filed Mar 6, 2024 00:34 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	50,187	$0.00	$0.00	Disclosure SEC source: 0001765581-24-000013 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,245 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document
January 17, 2024 Filed Jan 19, 2024 23:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	12,245	$119.13	$1,458,746.85	Disclosure SEC source: 0001784606-24-000004 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 402,058 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document
January 17, 2024 Filed Jan 19, 2024 23:21 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	26,545	$0.00	$0.00	Disclosure SEC source: 0001784606-24-000004 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414,303 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 137 ordinary shares and 37 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 31, 2023 and November 30, 2023, respectively. Read SEC document
May 09, 2023 Filed May 12, 2023 01:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028876 · doc4.xml · derivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Common Stock · 23,243 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028876 · doc4.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,243 shares Expires 2033-05-03 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F3 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	183,434	$0.00 Strike: $4.04	$0.00	Disclosure SEC source: 0001209191-23-028876 · doc4.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,434 Underlying: Common Stock · 183,434 shares Expires 2032-03-07 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 09, 2023 Filed May 12, 2023 01:04 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherDirector Stock Option (right to buy) · Derivative	183,434	$0.00 Strike: $4.04	$0.00	Disclosure SEC source: 0001209191-23-028876 · doc4.xml · derivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 183,434 shares Expires 2032-03-07 F1 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. F2 · derivative.exercise_date: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F1 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
May 04, 2023 Filed May 5, 2023 00:13 UTC	ACELYRIN, Inc. SLRN · Entity 79310	GrantDirector Stock Option (right to buy) · Derivative	23,243	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-027526 · doc4.xml · derivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,243 Underlying: Class A Common · 23,243 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document
March 05, 2023 Filed Mar 8, 2023 01:44 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Tax withholdingOrdinary Shares	21,882	$142.78	$3,124,311.96	Disclosure SEC source: 0001765581-23-000015 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,584 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document
March 03, 2023 Filed Mar 8, 2023 01:44 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	GrantOrdinary Shares	42,388	$0.00	$0.00	Disclosure SEC source: 0001765581-23-000015 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,466 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document
February 01, 2023 Filed Feb 3, 2023 23:45 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$155.79	$155,790.00	Disclosure SEC source: 0001765581-23-000006 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,078 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,000	$160.00	$320,000.00	Disclosure SEC source: 0001765581-23-000002 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,078 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:41 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$159.59	$159,590.00	Disclosure SEC source: 0001765581-23-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 370,078 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
December 01, 2022 Filed Dec 5, 2022 22:03 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$157.00	$157,000.00	Disclosure SEC source: 0001765581-22-000128 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,078 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 50 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2022. Read SEC document
November 10, 2022 Filed Nov 14, 2022 22:39 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,000	$150.00	$300,000.00	Disclosure SEC source: 0001765581-22-000118 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,028 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
October 03, 2022 Filed Oct 5, 2022 22:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	62,905	$0.00 Strike: $59.13	$0.00	Disclosure SEC source: 0001765581-22-000116 · edgardoc.xml · derivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 62,905 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. Read SEC document
October 03, 2022 Filed Oct 5, 2022 22:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	7,748	$135.80	$1,052,213.27	Disclosure SEC source: 0001765581-22-000116 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,028 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.57 to $136.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
October 03, 2022 Filed Oct 5, 2022 22:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	23,646	$135.18	$3,196,385.88	Disclosure SEC source: 0001765581-22-000116 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,776 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.57 to $135.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
October 03, 2022 Filed Oct 5, 2022 22:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	13,791	$134.02	$1,848,307.06	Disclosure SEC source: 0001765581-22-000116 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,422 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.56 to $134.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
October 03, 2022 Filed Oct 5, 2022 22:43 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	62,905	$59.13	$3,719,572.65	Disclosure SEC source: 0001765581-22-000116 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $59.13	$0.00	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · derivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,905 Underlying: Ordinary Shares · 9,700 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	542	$155.22	$84,129.24	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,308 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F6 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $155.095 to $155.74. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	474	$154.31	$73,142.94	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,850 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.93 to $154.66. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,170	$153.13	$179,162.10	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,324 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.87 to $153.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	4,517	$152.41	$688,435.97	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,494 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $151.87 to $152.85. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$59.13	$573,561.00	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 06, 2022 Filed Sep 8, 2022 20:55 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$155.10	$155,100.00	Disclosure SEC source: 0001765581-22-000111 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,311 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	68	$0.00 Strike: $59.13	$0.00	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · derivative · entry 8 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,605 Underlying: Ordinary Shares · 68 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · derivative.exercise_date: This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,632	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · derivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$154.94	$154,940.00	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,311 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,100	$155.27	$170,794.80	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,311 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $155.015 to $155.66. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,601	$154.50	$401,858.40	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,411 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.01 to $154.95. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	2,600	$153.48	$399,052.16	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,012 F1 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.01 to $153.935. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	68	$59.13	$4,020.84	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:58 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,632	$46.83	$451,066.56	Disclosure SEC source: 0001765581-22-000073 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,700	$0.00 Strike: $46.83	$0.00	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · derivative · entry 6 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,700 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,500	$160.00	$240,000.00	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · nonDerivative · entry 5 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,912 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$156.95	$156,950.00	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · nonDerivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,412 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	436	$157.13	$68,508.94	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,412 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $157.05 to $157.36. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	5,839	$156.65	$914,686.94	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,848 F2 · kind: Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.05 to $157.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document
July 05, 2022 Filed Jul 7, 2022 21:11 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	Exercise / conversionOrdinary Shares	9,700	$46.83	$454,251.00	Disclosure SEC source: 0001765581-22-000067 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
June 02, 2022 Filed Jun 3, 2022 19:04 UTC	Jazz Pharmaceuticals plc JAZZ · Entity 818	SaleOrdinary Shares	1,000	$150.00	$150,000.00	Disclosure SEC source: 0001765581-22-000053 · edgardoc.xml · nonDerivative · entry 7 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,987 F7 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.